Rosoxacin
This article needs additional citations for verification. (August 2014) |
Clinical data | |
---|---|
Trade names | Eradacil |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
JSmol) | |
Melting point | 290 °C (554 °F) |
| |
| |
(what is this?) (verify) |
Rosoxacin (also known as acrosoxacin, tradename Eradacil) is a
sexually transmitted diseases
. Rosoxacin is not available in the United States.
It was developed in 1978 by George Lesher and his colleagues at
It is classified as a first generation quinolone.[3]
Synthesis
The synthesis of rosoxacin begins with a modified
Gould-Jacobs reaction with methoxymethylenemalonate ester to form the 4-hydroxyquinoline ring, and then alkylation with ethyl iodide
and saponification of the ester to complete the synthesis of the antibacterial agent rosoxacin (4).
See also
- Fluoroquinolone
References
- .
- .
- PMID 2173670.
- ^ US 3907808, Lescher Y, Carabateas PM, "1,4-Dihydro-4-oxo-7-pyridyl-3-quinolinecarboxylic acid derivatives", issued 23 September 1975, assigned to STWB Inc.; Chem. Abstr., 84, 43880p (1975).